The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress

doi:10.19401/j.cnki.1007-3639.2019.06.001

China Oncology ›› 2019, Vol. 29 ›› Issue (6): 401-411.doi: 10.19401/j.cnki.1007-3639.2019.06.001

Previous Articles Next Articles

The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress

YANG Ke¹, ZHENG Rong¹, LIN Yansong²

1. Department of Nuclear Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China; 2. Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Online:2019-06-30 Published:2019-07-12
Contact: LIN Yansong E-mail: linys@pumch.cn

Abstract

Abstract: Compared with adults differentiated thyroid cancer (aDTC), children differentiated thyroid cancer (cDTC) exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. However, previous guidelines for the management of thyroid nodules and cancers were based on the evidence of aDTC. The American Thyroid Association (ATA) children guidelines provide recommendations for the evaluation and management of cDTC to help guide the clinical decisions. This article interprets the pathology and clinical outcomes of cDTC, risk stratification, postoperative assessments, decisions regarding ¹³¹I therapy and follow-up in ATA children guidelines as well as updated literature about cDTC in recent years.

Key words: Management guidelines for children with thyroid cancer, Differentiated thyroid cancer, Radioactive iodine therapy, Research progress

YANG Ke, ZHENG Rong, LIN Yansong. The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress[J]. China Oncology, 2019, 29(6): 401-411.

[1]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[2]	LI Min, WEN Peng, QIAN Qiuqin, QIN Ang, ZENG Li, SHI Feng. Clinical study of iodine-125 seeds implantation in the treatment of lymph node metastasis of radioactive iodine- refractory differentiated thyroid cancer [J]. China Oncology, 2020, 30(2): 122-127.
[3]	MU Zhuanzhuan , LI Zheng , ZHANG Xin , LIN Yansong . The effect of empiric ¹³¹ I therapy in papillary thyroid cancer patients with pulmonary metastasis [J]. China Oncology, 2020, 30(12): 991-995.
[4]	ZHANG Liyang, LIU Chunhao, CAO Yue, LIU Hongfeng, GAO Weisheng, LI Xiaoyi. Experiences of 125 cases of re-operated persistent/recurrent differentiated thyroid cancer [J]. China Oncology, 2019, 29(6): 412-417.
[5]	GAO Luying, LIN Yansong, JIANG Yuxin, LI Jianchu, LI Hui, ZHANG Bo, LIU Ruyu, XI Xuehua, GAO Qiong, WANG Ying, ZHAO Ruina. Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer [J]. China Oncology, 2019, 29(6): 418-422.
[6]	ZHANG Na, LIN Yansong, LIANG Jun. The clinical significance of thyroglobulin antibody measurement in 131I therapy of differentiated thyroid carcinoma [J]. China Oncology, 2019, 29(6): 452-456.
[7]	SONG Juanjuan, LIU Yanqing, LIN Yansong. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose ¹³¹I therapy [J]. China Oncology, 2019, 29(3): 207-211.
[8]	LI Hui, LIN Yansong. Molecular imaging of nuclear medicine in differentiated thyroid cancer: current status and future direction [J]. China Oncology, 2018, 28(7): 481-486.
[9]	ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al. The value of ¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy [J]. China Oncology, 2018, 28(7): 505-510.
[10]	HU Houyang, LIANG Jun, ZHANG Teng, et al. Correlation between minimal extrathyroid invasion and recurrence in differentiated thyroid cancer [J]. China Oncology, 2017, 27(12): 946-952.
[11]	LIN Yansong, WANG Chen, LI Hui, et al. The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks [J]. China Oncology, 2016, 26(9): 721-726.
[12]	LI Xuena, YIN Yafu, DU Bulin, et al. The correlation study between the glucose metabolism of 18F-FDG PET/CT incidental thyroid cancer and clinicopathologic characteristics [J]. China Oncology, 2016, 26(6): 527-532.
[13]	LIN Yansong, LI Jiao. The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New progress in radioactive iodine therapy of differentiated thyroid carcinoma [J]. China Oncology, 2016, 26(1): 1-12.
[14]	LI Xiaoyi. The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Surgery part [J]. China Oncology, 2016, 26(1): 13-18.
[15]	GUO Ye. The molecular-targeted therapy in advanced differentiated thyroid cancer [J]. China Oncology, 2016, 26(1): 31-34.

The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments